Time filter

Source Type

Watanabe H.,Japan Labour Health and Welfare Organization
Nihon Hoshasen Gijutsu Gakkai zasshi | Year: 2013

Decay-in-storage for radioactive waste including that of nuclear medicine has not been implemented in Japan. Therefore, all medical radioactive waste is collected and stored at the Japan Radioisotope Association Takizawa laboratory, even if the radioactivity has already decayed out. To clarify the current situation between Takizawa village and Takizawa laboratory, we investigated the radiation management status and risk communication activities at the laboratory via a questionnaire and site visiting survey in June 2010. Takizawa laboratory continues to maintain an interactive relationship with local residents. As a result, Takizawa village permitted the acceptance of new medical radioactive waste containing Sr-89 and Y-90. However, the village did not accept any non-medical radioactive waste such as waste from research laboratories. To implement decay-in-storage in Japan, it is important to obtain agreement with all stakeholders. We must continue to exert sincere efforts to acquire the trust of all stakeholders.

Kawamori R.,Juntendo University | Kaku K.,Osaka Medical College | Hanafusa T.,Dainippon Sumitomo | Kashiwabara D.,Jikei University School of Medicine | And 2 more authors.
Journal of Diabetes Investigation | Year: 2012

Aims/Introduction: Repaglinide is a short-acting insulin secretagogue. We assessed the efficacy and safety of repaglinide in comparison with nateglinide in Japanese patients with type 2 diabetes previously treated with diet and exercise. Materials and Methods: In this 16-week randomized, multicenter, double-blind, parallel-group, active-controlled superiority trial, Japanese patients with type 2 diabetes and glycated hemoglobin (HbA 1c) of ≥6.9 and ≤9.4% were enrolled. Patients were randomly assigned to receive 0.5mg repaglinide (n=64) or 90mg nateglinide (n=66) three times a day. The primary end-point was changes in HbA 1c from baseline to the end of treatment. Results: Mean reductions of HbA 1c were significantly greater for the repaglinide group than the nateglinide group (-1.17±0.62 vs -0.81±0.39%, P<0.001). The target HbA 1c values of <6.9% were achieved by 75.0% of the repaglinide group vs 59.1% for nateglinide. Mean changes in fasting plasma glucose also showed significantly greater efficacy for repaglinide than nateglinide (-26.0±20.9 vs -18.3±17.8mg/dL, P<0.001). There were no differences in the adverse event rates between the repaglinide and the nateglinide group, by 57.8% (37/64) and 60.6% (40/66), respectively. Incidences of hypoglycemic symptoms were 17.2% (11/64, 28 events) in the repaglinide group and 6.1% (4/66, 20 events) in the nateglinide group, respectively. Conclusions: In type 2 diabetic patients treated with diet and exercise, repaglinide monotherapy gives greater glycemic improvement than nateglinide monotherapy in reducing HbA 1c and fasting plasma glucose values after 16weeks. This trial was registered with JapicCTI (no. JapicCTI-080521). © 2011 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd.

Background : In recent years, the glucagon-like peptide-1 receptor agonist liraglutide has become available for clinical use and appears to hold promise as a novel therapeutic option that offers potent glucose lowering without causing significant weight gain or hypoglycemia, with additional potential to arrest the progressive deterioration of pancreatic β-cell function, unlike conventional anti-diabetic therapy, in type 2 diabetic patients. Methods : The results of clinical trials of liraglutide conducted to date in Japanese patients were reviewed, and clinical settings were explored in which the benefit of liraglutide could be maximized. Results : Data from clinical trials suggested that obese patients with early-stage type 2 diabetes might benefit most from the use of liraglutide through reductions in both HbA1c and body weight. Consistent with the trial results, subsequent clinical experience suggested a number of potential clinical settings in which the benefit of liraglutide could be maximized : liraglutide monotherapy may represent a frontline option for obese patients with early-stage type 2 diabetes requiring long-term therapy, a safe and effective alternative to combination therapy with multiple OADs associated with weight gain and hypoglycemia, and an alternative combination therapy with multiple OADs to promote better QOL. Conclusions : Liraglutide monotherapy may represent a frontline option in patients with early-stage type 2 diabetes, particularly those with obesity, as well as a safe and effective alternative for combination therapy employing multiple anti-diabetic drugs even in those with good glycemic control. Further clinical experience will help clarify the role of liraglutide in a real-world setting.

Hattori Y.,Nippon Medical School | Tahara S.,Nippon Medical School | Ishii Y.,Nippon Medical School | Kitamura T.,Nippon Medical School | And 5 more authors.
Journal of Clinical Endocrinology and Metabolism | Year: 2013

Context: IgG4-related hypophysitis is a novel clinical disease entity, which is typically complicated by hypopituitarism. Objective: The objective of the study was to describe a novel case of IgG4-related hypophysitis without pituitary insufficiency and summarize the current relevant literature. Patient and Methods: A55-year-old Japanese man presented with an enlarged pituitary gland and bitemporal hemianopsia. Endocrine studies revealed normal pituitary function, although his serum IgG4 level was high. The patient underwent a transsphenoidal biopsy of the pituitary gland, and the pathological tissues were consistent with IgG4-related hypophysitis. Oral prednisolone therapy was started, and after 6 months, his serum IgG4 level decreased and visual field improved. Conclusion: We described the first case of IgG4-related hypophysitis without pituitary insufficiency. However, further case collection is needed to characterize the pathophysiology of IgG4-related hypophysitis. Copyright © 2013 by The Endocrine Society.

Mabuchi Y.,Wakayama Medical University | Yamamoto M.,Japan Labour Health and Welfare Organization | Minami S.,Wakayama Medical University | Umesaki N.,Wakayama Medical University
International Journal of Molecular Medicine | Year: 2010

We previously reported that activin A, not inhibin, was localized to endometrial tissues, and that the endometrium might be a major source of activin A during the menstrual cycle, using an immunohistochemical method. However, there are few detailed reports concerning the expression of inhibin subunits, activin receptors and Smad proteins in the ectopic endometrial tissues of endometriosis. In this study, our purpose was to evaluate the immunohistochemical localization of inhibin α-, βA-subunits, activin A, activin receptor, and Smad proteins in ovarian endometriosis. Tissue samples from ovarian endometriosis were obtained from 13 women. Normal endometrial tissues were obtained during the proliferative phase from 5 premenopausal women without endometriosis who were undergoing a hysterectomy for the treatment of uterine cervical intraepithelial neoplasia 3. We examined the immunohistochemical localization of inhibin/activin α-, βA-subunit, activin A, activin receptors types IA, IB, IIA, IIB, Smad2, Smad3 and Smad4 using an avidin-biotin-peroxidase complex technique. No immunostaining for the α-subunit of inhibin was observed in ovarian endometriosis and the normal endometrium. Positive immunostaining for the βA-subunit of inhibin, activin A, activin receptors types IA, IB, IIA, IIB, Smad2, Smad3 and Smad4 was observed in ovarian endometriosis and the normal endometrium. In conclusion, these results suggest that activin A, but not inhibins, is produced by ovarian endometriosis and the normal endometrium, and that the activin signal transduction system exists in both ovarian endometriosis and the normal endometrium.

Discover hidden collaborations